allogeneic CD7-CAR T cells

Allogeneic CD7-CAR T cells are genetically engineered, donor-derived chimeric antigen receptor (CAR) T-cell therapies designed to target CD7, a transmembrane glycoprotein highly expressed on malignant T cells, normal T cells, natural killer (NK) cells, and a subset of acute myeloid leukemia (AML) cells. Unlike autologous CAR-T therapies, allogeneic CD7-CAR T cells are manufactured from healthy donor T cells, offering an "off-the-shelf" treatment option that reduces manufacturing time and costs. To prevent fratricide (CAR-T cells killing each other due to CD7 expression) and graft-versus-host disease (GvHD), these cells typically undergo gene editing (such as CRISPR/Cas9 or base editing) to disrupt the expression of CD7 and the T-cell receptor (TCR). They are primarily investigated for the treatment of relapsed or refractory CD7-positive hematologic malignancies, including T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), and CD7-expressing acute myeloid leukemia (AML).

Other names

allogeneic CD7 CAR T cellsallogeneic CD7 CAR-T cellsallogeneic CD7-directed CAR T cellsallogeneic CD7-targeted CAR T cellsdonor-derived CD7 CAR-T cellsuniversal CD7 CAR-T cells